the first new therapy option for ALS – also known as motor neuron disease (MND) – since Mitsubishi Tanabe Pharma's intravenous Radicava (edaravone) was cleared by the FDA in 2017. An oral ...

and high annual cost of therapy. The oral version of Mitsubishi Tanabe's drug was approved by the FDA in May, and is expected to increase the number of patients treated with edaravone, reduce the ...